Carlos Gomez‐Roca

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 534 citations

Pharmacy, Oncology, Pharmacotherapy +14

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Céline Berthon, Emmanuel Raffoux, Xavier Thomas et al. · The Lancet Haematology · 2016 · 431 citations

Medicine, Hematology, Pharmacology +7

Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Anastasios Stathis, Emanuele Zucca, Mohamed Békradda et al. · Cancer Discovery · 2016 · 381 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster et al. · Annals of Oncology · 2017 · 253 citations · Full text

Medicine, Oncology, Pharmacology +17